GSK-3: RELATIONSHIP TO CARDIOMETABOLIC DISEASES

Abstract

Aim -to study the levels of GSK-3 isoforms (GSK-3α and GSK-3β) in the blood serum of individuals with cardiometabolic diseases and their relationship with clinical and laboratory parameters.

Material and methods.The study included 83 patients (37 men and 46 women) with overweight or obesity, as well as arterial hypertension and hyperlipidemia. All the subjects were divided into two groups: group I - patients with overweight - 35 people, group II - patients with obesity - 48 people. The control group consisted of 42 healthy people with normal body weight. All the subjects were comparable in terms of gender and age.

Results. When studying GSK-3α and GSK-3β in the blood serum of the study groups, changes were found, characterized by a pronounced increase in the level of GSK-3α in patients with obesity and cardiometabolic disorders, a significant increase in the level of GSK-3β in patients with obesity and cardiometabolic disorders.In addition, the correlation analysis showed significant associations of GSK-3β with glucose levels in individuals with severe overweight, as well as GSK-3α with the waist-to-hip ratio and BMI in individuals with obesity.

Conclusion. Early diagnosis of changes in WNT signaling components, namely, GSK-3, in individuals with cardiometabolic disorders may become a promising direction in the implementation of comprehensive approaches to combat the risk of adverse cardiovascular outcomes.